ライフサイエンスコーパス: euglycemic

1 g/kg/min), separated by a 120-min break (all euglycemic).

2 mediators and NO were measured under clamped euglycemic (4-6 mmol/L) and hyperglycemic (9-11 mmol/L)

3 two 2-h hyperinsulinemic (812 +/- 50 pmol/L)-euglycemic (5 +/- 0.1 mmol/L) or hyperinsulinemic (812 +

4 ous pathways under hyperglycemic (26 mm) and euglycemic (5 mm) conditions.

5 Hyperinsulinemic euglycemic (5 mmol/L) and hypoglycemic (3 mmol/L) [1-(13

6 functional magnetic resonance imaging during euglycemic (5.0 mmol/L) and hypoglycemic (2.8 mmol/L) hy

7 d monocytes obtained during hyperinsulinemic-euglycemic (5.0 mmol/L)-hypoglycemic (2.6 mmol/L) clamps

8 bjects underwent a two-step hyperinsulinemic euglycemic (5.0 mmol/L)-hypoglycemic (2.8 mmol/L) glucos

9 Day 1 involved hyperinsulinemic euglycemic (90 mg/dL x 1 h), then hypoglycemic (54 mg/dL

10 ic participants underwent a hyperinsulinemic euglycemic (92+/-3 mg/dL) - hypoglycemic (53+/-1 mg/dL)

11 We determined the effects of three different euglycemic agents on HD progression using standard physi

12 Euglycemic agents targeting hypothalamic and energy regu

13 orated, to varying degrees, by the different euglycemic agents.

14 A hyperinsulinemic-euglycemic and a hyperglycemic clamp were performed in 1

15 offered insights into gluconeogenesis under euglycemic and diabetic conditions.

16 ssed glucose homeostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp studies and energy ex

17 ed metabolic cages, glucose tolerance tests, euglycemic and hyperglycemic clamps, as well as isolated

18 T1D patients (n = 49) were studied under euglycemic and hyperglycemic conditions at baseline and

19 olated with laser-capture microdissection in euglycemic and hyperglycemic HypoE mice.

20 ng (CGM) values, percentage of CGM values in euglycemic and hyperglycemic ranges, and mean amplitude

21 Day 2 involved similar morning euglycemic and hypoglycemic clamps, with saline infusion

22 d by antecedent recurrent hypoglycemia under euglycemic and hypoglycemic conditions in a rat model an

23 A, was not significantly different comparing euglycemic and hypoglycemic conditions in patients with

24 For this purpose, hyperinsulinemic euglycemic and hypoglycemic glucose clamps were performe

25 scular adhesion and augment atherogenesis in euglycemic apolipoprotein E knockout mice to a similar m

26 ate in the BD + IR/GI, and highest among the euglycemic BD and control subjects (F(3),(5)(5) = 4.57,

27 I), 14 BD subjects with T2DM (BD + T2DM), 15 euglycemic BD participants, and 11 euglycemic, nonpsychi

28 (IS; n = 10), determined by hyperinsulinemic-euglycemic clamp (>30% greater in IS compared with IR, P

29 s measured by a three-stage hyperinsulinemic-euglycemic clamp (4, 8, and 40 mU/m(2)/min) in 87 subjec

30 maging system combined with hyperinsulinemic euglycemic clamp (HEC) was used.

31 tients underwent a two-step hyperinsulinemic-euglycemic clamp (HEC) with glucose tracer and labeled g

32 vity was determined using a hyperinsulinemic-euglycemic clamp (SIClamp, insulin rate:120 mU/m2/min).

33 ous glucose tolerance test (four cohorts) or euglycemic clamp (three cohorts), and random-effects mod

34 ma Indians (P = 0.027) or a hyperinsulinemic-euglycemic clamp among 536 nondiabetic Native Americans

35 Hyperinsulinemic-euglycemic clamp analysis 8 weeks after lesioning showed

36 emale mice were assessed by hyperinsulinemic-euglycemic clamp analysis and indirect calorimetry and b

37 Hyperinsulinemic-euglycemic clamp analysis was used to analyze the role o

38 n type 1 diabetes using the hyperinsulinemic-euglycemic clamp and (31)P-MRS before, during, and after

39 ion were evaluated by a 3-h hyperinsulinemic-euglycemic clamp and a 2-h hyperglycemic clamp.

40 tion are not clear.METHODSA hyperinsulinemic-euglycemic clamp and a 3-hour oral glucose tolerance tes

41 Assessments by hyperinsulinemic-euglycemic clamp and a glucose tolerance test revealed n

42 d of each dietary period, a hyperinsulinemic-euglycemic clamp and an intravenous glucose tolerance te

43 sensitivity was measured by hyperinsulinemic-euglycemic clamp and insulin secretion by applying mathe

44 and glucose tolerance using hyperinsulinemic-euglycemic clamp and intravenous and oral glucose tolera

45 d insulin sensitivity using hyperinsulinemic-euglycemic clamp and muscle insulin receptor substrate a

46 I(clamp)) was studied using hyperinsulinemic-euglycemic clamp at baseline and at 4 months.

47 ty were assessed using the hyperinsulinemic- euglycemic clamp combined with the glucose tracer techni

48 hly insulin sensitive under hyperinsulinemic-euglycemic clamp conditions, eliminating insulin insensi

49 ogs during constant intravenous infusion and euglycemic clamp conditions.

50 erol, in combination with a hyperinsulinemic euglycemic clamp during the last 3 hrs.

51 The hyperinsulinemic-euglycemic clamp experiment showed that the TRPV1 KO mic

52 Hyperinsulinemic-euglycemic clamp experiments show, for the first time, t

53 Yet in insulin tolerance tests and euglycemic clamp experiments, NTE-1 did not enhance insu

54 nsulin tolerance tests, and hyperinsulinemic-euglycemic clamp experiments.

55 < 0.05) and negatively with hyperinsulinemic-euglycemic clamp glucose infusion rate (r = -0.28, P < 0

56 abolism, as assessed during hyperinsulinemic-euglycemic clamp in awake mice.

57 nfusion of insulin during a hyperinsulinemic-euglycemic clamp induced conspicuous ER stress in the 3-

58 ensitivity, measured by the hyperinsulinemic-euglycemic clamp method.

59 During hyperinsulinemic-euglycemic clamp of diabetic KKA(Y) mice, A(2B)R antagon

60 ect measures of insulin sensitivity, such as euglycemic clamp or insulin suppression test, in 2,764 E

61 legs before and after a 3-h hyperinsulinemic euglycemic clamp performed 3 h after a 45-min, one-legge

62 sal conditions and during a hyperinsulinemic-euglycemic clamp procedure (HECP), with and without conc

63 vity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose t

64 was evaluated by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable is

65 A two-stage hyperinsulinemic-euglycemic clamp procedure in conjunction with stable is

66 hr308) in 22 women during a hyperinsulinemic-euglycemic clamp procedure with and without concomitant

67 in glucose uptake during a hyperinsulinemic-euglycemic clamp procedure).

68 A hyperinsulinemic-euglycemic clamp procedure, in conjunction with glucose

69 was determined by using the hyperinsulinemic euglycemic clamp procedure.

70 The hyperinsulinemic euglycemic clamp revealed that VDR activation greatly in

71 Hyperinsulinemic-euglycemic clamp reveals an increased glucose infusion r

72 Hyperglycemic-euglycemic clamp studies and glucose tolerance testing r

73 learance were quantified by hyperinsulinemic euglycemic clamp studies and pyruvate tolerance tests.

74 Hyperinsulinemic-euglycemic clamp studies demonstrated that targeted disr

75 Hyperinsulinemic-euglycemic clamp studies indicate that in contrast to he

76 Hyperinsulinemic-euglycemic clamp studies reveal that the maintenance of

77 Hyperinsulinemic-euglycemic clamp studies revealed greater high-fat diet-

78 However, hyperinsulinemic euglycemic clamp studies revealed improved insulin sensi

79 Hyperinsulinemic-euglycemic clamp studies revealed significantly improved

80 sis on a high-fat diet, and hyperinsulinemic-euglycemic clamp studies revealed that insulin sensitivi

81 Hyperinsulinemic-euglycemic clamp studies show that BAM15 improves insuli

82 Furthermore, hyperinsulinemic euglycemic clamp studies showed no difference between Pr

83 Hyperinsulinemic-euglycemic clamp studies showed that adiponectin adminis

84 Hyperinsulinemic euglycemic clamp studies showed that the increase in hep

85 Hyperinsulinemic-euglycemic clamp studies suggest that DM199 increases wh

86 insulin tolerance tests and hyperinsulinemic-euglycemic clamp studies were performed with heterozygou

87 harvested before and after hyperinsulinemic-euglycemic clamp studies, at baseline and after 3-month

88 insulin sensitivity during hyperinsulinemic-euglycemic clamp studies, which was associated with incr

89 ic subjects was assessed by hyperinsulinemic-euglycemic clamp studies.

90 insulin sensitivity during hyperinsulinemic euglycemic clamp studies.

91 sitivity were determined by hyperinsulinemic-euglycemic clamp studies.

92 and glucose levels through hyperinsulinemic, euglycemic clamp studies.

93 abolism was investigated by hyperinsulinemic-euglycemic clamp studies.

94 high exogenous insulin over the course of a euglycemic clamp study, indicating that hypoinsulinemia

95 In addition, a hyperinsulinemic-euglycemic clamp suggests that intracerebroventricular d

96 t was assessed by using the hyperinsulinemic-euglycemic clamp technique.

97 n with isotope dilution and hyperinsulinemic-euglycemic clamp techniques.

98 reased more than 30% in the hyperinsulinemic-euglycemic clamp test.

99 was administered and a 3-h hyperinsulinemic-euglycemic clamp was commenced ("fed" period).

100 cose infusion rate during a hyperinsulinemic-euglycemic clamp was increased by 50% in high-fat diet-f

101 Insulin sensitivity during euglycemic clamp was increased, whereas total body fat m

102 Wistar rats assessed by the hyperinsulinemic-euglycemic clamp was minimally affected by pioglitazone

103 During the last 2 h, a hyperinsulinemic-euglycemic clamp was performed.

104 A hyperinsulinemic euglycemic clamp was used to compare tissue-specific cha

105 ensitivity (measured with a hyperinsulinemic euglycemic clamp with [6,6-(2)H(2)]-glucose), and oral g

106 nsitivity was assessed by a hyperinsulinemic-euglycemic clamp with [6,6-(2)H2]-glucose infusion.

107 insulin sensitivity using a hyperinsulinemic euglycemic clamp with a glucose isotope tracer before an

108 A hyperinsulinemic-euglycemic clamp with femoral arteriovenous balance and

109 hed Cs underwent a two-step hyperinsulinemic-euglycemic clamp with skeletal muscle biopsies and indir

110 nsitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tracer infusion) in

111 tep (10 and 20 mU/m(2)/min) hyperinsulinemic-euglycemic clamp with stable isotopes, in 6-week postpar

112 glucose tolerance test and hyperinsulinemic euglycemic clamp) and imaging studies (MRI, DEXA, (1)H-N

113 (LPB) under postabsorptive (hypoinsulinemic-euglycemic clamp) and postprandial (hyperinsulinemic hyp

114 randial (hyperinsulinemic hyperaminoacidemic-euglycemic clamp) conditions.

115 = 64] or insulin-resistant [IR] [n = 79] by euglycemic clamp) received four mixed meals over 14 h wi

116 ithout insulin stimulation (hyperinsulinemic-euglycemic clamp) using [18F]fluorodeoxyglucose scanning

117 er and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the tr

118 on insulin sensitivity (by hyperinsulinemic euglycemic clamp), body composition (by dual-energy X-ra

119 ol at baseline and during a hyperinsulinemic-euglycemic clamp), lipid oxidation (indirect calorimetry

120 ty was analyzed by a 2-step hyperinsulinemic euglycemic clamp, and postprandial interorgan crosstalk

121 sensitivity, as measured by hyperinsulinemic-euglycemic clamp, and skeletal muscle mitochondrial func

122 nthropometric measures, FFAs, IR measured by euglycemic clamp, blood pressure, fasting serum lipids,

123 During the hyperinsulinemic-euglycemic clamp, retrodialysis of dexamethasone into th

124 n sensitive, as measured by hyperinsulinemic-euglycemic clamp, than C57BL/6 wild-type mice.

125 ontrols (n = 6) underwent a hyperinsulinemic-euglycemic clamp, VO2max test, dual-energy X-ray absorpt

126 Using the hyperglycemic and euglycemic clamp, we demonstrated impaired beta-cell fun

127 in resistance assessed by a hyperinsulinemic-euglycemic clamp, which could mostly be attributed to in

128 g glucose disposal during a hyperinsulinemic-euglycemic clamp, while decreasing hepatic glucose produ

129 tivity was measured using a hyperinsulinemic-euglycemic clamp.

130 at baseline and during the hyperinsulinemic-euglycemic clamp.

131 lue) was determined using a hyperinsulinemic-euglycemic clamp.

132 cle glucose uptake during a hyperinsulinemic-euglycemic clamp.

133 ucose production during the hyperinsulinemic-euglycemic clamp.

134 nd increased rate of glucose disposal during euglycemic clamp.

135 sensitivity measured by the hyperinsulinemic-euglycemic clamp.

136 5-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.

137 3-h basal period and a 3-h hyperinsulinemic-euglycemic clamp.

138 ween a baseline study and a hyperinsulinemic euglycemic clamp.

139 uscles at the baseline of a hyperinsulinemic-euglycemic clamp.

140 ady-state conditions with a hyperinsulinemic euglycemic clamp.

141 y [(18)F]FDG-PET/MRI during hyperinsulinemic-euglycemic clamp.

142 esistance was assessed by a hyperinsulinemic-euglycemic clamp.

143 metabolism was evaluated by hyperinsulinemic-euglycemic clamp.

144 rameters were determined by hyperinsulinemic-euglycemic clamp.

145 sal (M) measured during the hyperinsulinemic-euglycemic clamp.

146 system was performed under hyperinsulinemic-euglycemic clamp.

147 ose uptake as measured by a hyperinsulinemic-euglycemic clamp.

148 ric characteristics and were studied using a euglycemic clamp.

149 cle glucose uptake during a hyperinsulinemic-euglycemic clamp.

150 rin-infusion (high FFA) and hyperinsulinemic-euglycemic clamping (low FFA) in a randomized crossover-

151 Hyperinsulinemic-euglycemic clamping studies revealed that ECSHIP2(Delta/

152 polygenic obesity underwent hyperinsulinemic-euglycemic clamping with concomitant adipose tissue (AT)

153 udies comparing fasting and hyperinsulinemic-euglycemic clamping with tracer infusions.

154 s confirmed with the use of hyperinsulinemic euglycemic clamping, showing a glucose infusion rate amo

155 istration of tracers during hyperinsulinemic-euglycemic clamping.

156 nd in wild-type mice during hyperinsulinemic-euglycemic clamping.

157 meal tolerance test (MMT), hyperinsulinemic-euglycemic clamps (HECs), and skeletal muscle and white

158 rom liver insulin resistance, as revealed by euglycemic clamps and hepatic insulin signaling determin

159 with markers of insulin resistance in vivo (euglycemic clamps and HOMA of insulin resistance), and t

160 Hyperinsulinemic-euglycemic clamps and insulin tolerance testing showed s

161 Hyperinsulinemic-euglycemic clamps and signaling studies were performed f

162 t research tests, including hyperinsulinemic-euglycemic clamps and vastus lateralis biopsies.

163 e treatment, mice underwent hyperinsulinemic-euglycemic clamps combined with radiolabeled glucose to

164 Hyperinsulinemic-euglycemic clamps confirmed enhanced insulin sensitivity

165 tivity was determined using hyperinsulinemic-euglycemic clamps in conscious mice.

166 Hyperinsulinemic-euglycemic clamps in DIO mice revealed that MTZ increase

167 tolerance tests (GTTs) and hyperinsulinemic-euglycemic clamps in mouse models of type 2 diabetes.

168 to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n = 10/gr

169 ion in IR was studied using hyperinsulinemic-euglycemic clamps on integrin alpha(2)beta(1)-null (itga

170 he following: 1) two 90-min hyperinsulinemic-euglycemic clamps plus naloxone infusion (control); 2) t

171 Hyperinsulinemic-euglycemic clamps revealed no differences in insulin sen

172 of insulin resistance using hyperinsulinemic-euglycemic clamps revealed no significant differences in

173 We used hyperinsulinemic-euglycemic clamps to show a bona fide circadian rhythm o

174 to assess IMCL content and hyperinsulinemic-euglycemic clamps using [6,6-(2)H(2)] glucose to assess

175 and insulin sensitivity by hyperinsulinemic-euglycemic clamps were examined.

176 e-tolerance test (OGTT) and hyperinsulinemic-euglycemic clamps were performed to assess beta-cell fun

177 Hyperinsulinemic euglycemic clamps were performed to determine whole-body

178 -ribofuranoside (AICAR; 8 mg.kg(-1).min(-1))-euglycemic clamps were performed to elicit an increase i

179 treatment, oral glucose tolerance tests and euglycemic clamps were performed, and histochemical anal

180 Hyperinsulinemic-euglycemic clamps were used to assess insulin sensitivit

181 ethionine restriction (MR), hyperinsulinemic-euglycemic clamps were used to examine the effect of the

182 insulin administration and hyperinsulinemic-euglycemic clamps with [(3)H]glucose infusion.

183 First, we performed hyperinsulinemic-euglycemic clamps with concurrent hippocampal microdialy

184 wenty-one men underwent two hyperinsulinemic-euglycemic clamps with d-[6,6-(2)H2]glucose infusion to

185 on (control); 2) two 90-min hyperinsulinemic-euglycemic clamps with exercise at 60% Vo(2max), plus na

186 mic-hypoglycemic and paired hyperinsulinemic-euglycemic clamps with infusion of 6,6-(2)H2-glucose and

187 ctroscopy before and during hyperinsulinemic-euglycemic clamps with isotope dilution.

188 Conscious dogs underwent euglycemic clamps with tracer and hepatic balance measur

189 ), insulin sensitivity (via hyperinsulinemic-euglycemic clamps), and insulin secretion [via intraveno

190 sing direct measures (i.e., hyperinsulinemic-euglycemic clamps), we examined the relationships betwee

191 disposal rate (measured by hyperinsulinemic-euglycemic clamps).

192 nd insulin tolerance tests, hyperinsulinemic-euglycemic clamps, and insulin signaling studies.

193 on in isolated hepatocytes, hyperinsulinemic-euglycemic clamps, liver triglyceride content, and liver

194 olic phenotyping, including hyperinsulinemic-euglycemic clamps, magnetic resonance spectroscopy, musc

195 Using hyperinsulinemic-euglycemic clamps, we studied insulin action in Liv-DGAT

196 as assessed with the use of hyperinsulinemic-euglycemic clamps.

197 and 6 weeks as measured by hyperinsulinemic euglycemic clamps.

198 insulin tolerance tests and hyperinsulinemic-euglycemic clamps.

199 e tolerance test and during hyperinsulinemic-euglycemic clamps.

200 Under euglycemic conditions glutamine uptake doubled, but ATP

201 During hypoglycemia, compared with baseline euglycemic conditions, 1) baroreflex sensitivity decreas

202 Under hyperinsulinemic-euglycemic conditions, hepatic insulin response was ~10-

203 aits of tumor growth, even after a return to euglycemic conditions.

204 but there is increasing evidence that tight euglycemic control is associated with detrimental outcom

205 Tight euglycemic control was rapidly implemented in intensive

206 prazolam or day 1 hypoglycemia compared with euglycemic control.

207 Day 2 consisted of a 90-min euglycemic cycling exercise at 50% VO2max Tritiated gluc

208 Day 2 consisted of 90-min euglycemic cycling exercise at 50% VO2max.

209 e evaluated cardiovascular function in young euglycemic Dpp4(-/-) mice and in older, high fat-fed, di

210 Young euglycemic Dpp4(-/-) mice exhibited a cardioprotective r

211 Taken together, these euglycemic effects of salidroside may due to repression

212 insulin sensitivity from a hyperinsulinemic-euglycemic (EU) clamp, and glucose counterregulatory res

213 anhydrase II (CAII)(Cre);Pdx1(Fl) mice were euglycemic for the first 2 postnatal weeks but showed mo

214 sensitivity was assessed by hyperinsulinemic-euglycemic glucose clamp before and after intranasal app

215 >/=2 of the following: tubular proteinuria, euglycemic glycosuria, increased urinary phosphate, and

216 Hyperglycemic (HG) and hyperinsulinemic-euglycemic (HI) clamps were performed to assess GSIS and

217 tal days in a randomized order involving 2-h euglycemic-hyperglycemic clamps with coadministration of

218 Insulin sensitivity was assessed with euglycemic-hyperinsulemic clamps.

219 at in 10 and 11 adults, respectively, during euglycemic hyperinsulinemia or after oral niacin to supp

220 study with [(18)F]-fluorodeoxyglucose during euglycemic hyperinsulinemia.

221 In this prospective study, euglycemic hyperinsulinemic clamp (EHC) was performed at

222 ere studied before and 1 month after RYGB by euglycemic hyperinsulinemic clamp (EHC), by intravenous

223 ; P = 0.21), or glucose disposal rates under euglycemic hyperinsulinemic clamp conditions (SMD: 0.00;

224 seline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique.

225 ty in liver, muscle, and adipose tissue by a euglycemic hyperinsulinemic clamp with 3-(3)H-glucose.

226 nd hepatic glucose production as assessed by euglycemic hyperinsulinemic clamp.

227 SI was measured using euglycemic-hyperinsulinemic clamp (EGC), before (week 0

228 Euglycemic-hyperinsulinemic clamp (EHC) was preformed to

229 by isotope dilution, insulin sensitivity by euglycemic-hyperinsulinemic clamp (steady-state glucose

230 Here we show that initiation of a euglycemic-hyperinsulinemic clamp 4 h after single-legge

231 A euglycemic-hyperinsulinemic clamp and skeletal muscle bi

232 ence in change in IR assessed using a 2-step euglycemic-hyperinsulinemic clamp combined with infusion

233 is of glucose homeostasis was assessed using euglycemic-hyperinsulinemic clamp coupled with tracer ra

234 estigate this, eight healthy men underwent a euglycemic-hyperinsulinemic clamp on 2 separate days: on

235 Euglycemic-hyperinsulinemic clamp studies confirmed the

236 Euglycemic-hyperinsulinemic clamp studies demonstrate th

237 re assessed before (basal period) and during euglycemic-hyperinsulinemic clamp studies.

238 entions, we conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin se

239 extensor digitorum longus muscle during the euglycemic-hyperinsulinemic clamp was increased in lean

240 , whole-body and muscle insulin sensitivity (euglycemic-hyperinsulinemic clamp with 2-deoxyglucose) a

241 glucose metabolism (insulin tolerance test, euglycemic-hyperinsulinemic clamp, and hepatic expressio

242 ripheral insulin sensitivity was analyzed by euglycemic-hyperinsulinemic clamp, and molecular tools w

243 A euglycemic-hyperinsulinemic clamp, muscle biopsy specime

244 Thirty patients at risk for CIM underwent euglycemic-hyperinsulinemic clamp, muscle microdialysis

245 During euglycemic-hyperinsulinemic clamp, there is no suppressi

246 gated the association of genetic scores with euglycemic-hyperinsulinemic clamp- and oral glucose tole

247 insulin sensitivity was quantitated with the euglycemic-hyperinsulinemic clamp.

248 travenous glucose tolerance test (IVGTT) and euglycemic-hyperinsulinemic clamp.

249 lucose production is impaired as assessed by euglycemic-hyperinsulinemic clamp.

250 Subjects were also studied by euglycemic-hyperinsulinemic clamps performed at rest and

251 3.6 years) pre- and 3 months post-RYGB, and euglycemic-hyperinsulinemic clamps were used to assess i

252 on insulin sensitivity, as measured by using euglycemic-hyperinsulinemic clamps with infusion of [6,6

253 ulated by insulin in vivo in mice undergoing euglycemic-hyperinsulinemic clamps, being highly up-regu

254 edly enhanced glucose uptake measured during euglycemic-hyperinsulinemic clamps, suggesting a role of

255 alysis with oral glucose tolerance tests and euglycemic-hyperinsulinemic clamps.

256 y, and determined systemic glucose uptake by euglycemic-hyperinsulinemic glucose clamp in 15 normal-w

257 atic insulin resistance, as verified using a euglycemic/hyperinsulinemic clamp.

258 Glucose metabolism was not stimulated during euglycemic-hyperinsulinergic clamp.

259 RI) combined with a stepped hyperinsulinemic euglycemic-hypoglycemic clamp and behavioral measures of

260 s protein ingestion concomitantly stimulates euglycemic insulin and glucagon secretion.

261 A 2-stage hyperinsulinemic-euglycemic insulin clamp was used to measure insulin sen

262 insulin sensitivity, were assessed during a euglycemic insulin clamp with 3-[(3) H] glucose.

263 with the following studies: liver (1) H-MRS; euglycemic insulin clamp with measurement of glucose tur

264 se and 11 T2DM subjects received 1) OGTT, 2) euglycemic insulin clamp with muscle biopsy, and 3) (1)H

265 ody insulin clearance were measured during a euglycemic insulin clamp.

266 sensitivity (M/I ratio) was measured by the euglycemic insulin clamp.

267 ed an oral glucose tolerance test (OGTT) and euglycemic insulin clamp.

268 sting conditions and separately during a 6-h euglycemic insulin infusion at 40 mU . m(-2) . min(-1).

269 ded in nonobese and obese groups, received a euglycemic insulin-clamp (40 mU/m(2) . min) and an oral

270 The IPGR group remained lean, euglycemic, insulin sensitive, and active while maintain

271 nd visceral fat (P < 0.0002) while remaining euglycemic, insulin sensitive, inactive, and exhibiting

272 ss the mechanisms by which these drugs cause euglycemic ketoacidosis and hyperglucagonemia and stimul

273 been raised about their potential to induce euglycemic ketoacidosis and to increase both glucose pro

274 dehydration as a potential target to prevent euglycemic ketoacidosis associated with SGLT2i.

275 without risk: SGLT2 inhibitors predispose to euglycemic ketoacidosis in those with type 2 diabetes an

276 Important risks of SGLT2 inhibitors include euglycemic ketoacidosis, genital mycotic infections, and

277 cose increased from moderate hypoglycemia to euglycemic levels, whereas ERG b-wave sensitivity improv

278 hen plasma glucose concentrations rise above euglycemic levels.

279 T2DM), 15 euglycemic BD participants, and 11 euglycemic, nonpsychiatric control.

280 11beta-HSD1 activity is sustained, unlike in euglycemic obesity.

281 Day 1 consisted of morning and afternoon 2-h euglycemic or 2.9 mmol/L hypoglycemic clamps with or wit

282 rylation by autocrine IGF-1 occur equally in euglycemic or hyperglycemic conditions, suggesting that

283 f morning and afternoon 2-h hyperinsulinemic-euglycemic or hypoglycemic clamps with or without 1 mg a

284 sessed by using a two-stage hyperinsulinemic-euglycemic pancreatic clamp procedure in conjunction wit

285 nd insulin sensitivity were performed during euglycemic pancreatic clamp studies following diazoxide

286 stages 1 and 2 of a 3-stage hyperinsulinemic euglycemic pancreatic clamp).

287 Rats were studied by euglycemic pancreatic clamps and concomitant infusion of

288 e BD + IR/GI subjects had lower NAA than the euglycemic participants (t(4)(3) = 2.13, p = .04).

289 ignificant (p = 0.004) prolongation of their euglycemic period (by 6 weeks; up to 18 weeks of age) co

290 Constrictions of venules from euglycemic pigs to endothelin-1 (ET-1), thromboxane anal

291 For in vitro hyperglycemia, vessels from euglycemic pigs were exposed to high glucose (25 mmol/L)

292 arly all islet-KC mice (n = 15 of 16) became euglycemic posttransplant.

293 ucose, but subjects remained well within the euglycemic range.

294 glucose or 5-thio-D-glucose in anesthetized, euglycemic rats.

295 ased RAGE expression in T cells from at-risk euglycemic relatives who progress to T1D compared with h

296 recovery phase was allowed to reestablish a euglycemic state.

297 significant glucose lowering was observed in euglycemic subjects, a modest improvement was observed i

298 owever, the vast majority of carriers remain euglycemic through middle age.

299 vels are similarly regulated by a shift from euglycemic to hyperglycemic conditions.

300 In hyperinsulinemic-euglycemic wild type mice, renal Bmf expression was down